Reaction

Pulmonary Function Test Abnormal reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,542 reports · 71 co-occurring drugs

As of the last recalculation, Pulmonary Function Test Abnormal appears in 1,542 FAERS reports alongside 71 co-occurring drug terms. The strongest observed disproportionality signal is OSELTAMIVIR PHOSPHATE (PRR 111.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Oseltamivir Phosphate	179	111.8	112.6
Ciclesonide	102	108.2	109.0
Theophylline Anhydrous	90	104.0	104.8
Theophylline	81	100.3	101.1
Mepolizumab	290	96.8	97.4
Ceftriaxone Sodium	180	71.6	71.9
Azithromycin Monohydrate	191	70.5	70.8
Fluticasone Furoate And Vilanterol Trifenatate	158	65.9	66.2
Montelukast Sodium	404	60.3	60.5
Omalizumab	302	59.2	59.4
Pirfenidone	156	57.4	57.6
Azithromycin	145	53.6	53.8
Tamsulosin Hydrochloride	68	47.0	47.2
Dutasteride	27	45.6	45.8
Albuterol	318	44.8	44.9
Eplerenone	37	39.9	40.0
Budesonide	157	39.9	40.0
Azithromycin Dihydrate	154	39.3	39.4
Lumacaftor And Ivacaftor	24	38.4	38.5
Nintedanib	79	35.8	35.9
Tiotropium Bromide	295	35.7	35.8
Albuterol Sulfate	499	33.1	33.1
Ipratropium Bromide	78	31.0	31.1
Fluticasone Propionate And Salmeterol Xinafoate	124	30.2	30.3
Doxyclycline Hyclate	34	27.5	27.6
Dornase Alfa	38	26.8	26.8
Montelukast	150	26.6	26.7
Budesonide And Formoterol Fumarate Dihydrate	145	22.2	22.2
Finasteride	93	22.1	22.1
Tobramycin	37	21.3	21.3
Rabeprazole	34	21.2	21.2
Telmisartan	27	20.8	20.8
Rosuvastatin Calcium	42	20.7	20.7
Olmesartan Medoxomil	50	19.4	19.4
Apixaban	87	18.5	18.6
Umeclidinium	12	18.2	18.2
Prednisone	477	18.1	18.1
Elexacaftor, Tezacaftor, And Ivacaftor	15	16.4	16.4
Bisoprolol Fumarate	148	16.2	16.2
Tiotropium Bromide Inhalation Spray	13	15.8	15.8
0Xygen	55	15.6	15.6
Oxygen	55	15.6	15.6
Bleomycin Sulfate	10	13.1	13.2
Diclofenac Potassium, Film Coated	8	12.9	12.9
Diclofenac Potassium Tablets	8	12.9	12.9
Canakinumab	10	12.6	12.6
Tobramycin Solution	11	12.4	12.5
Cyclobenzaprine	44	12.2	12.2
Ceftriaxone	29	12.1	12.1
Tobramycin Sulfate	11	12.1	12.1
Diltiazem Hydrochloride Extended-Release Tablets	10	11.9	11.9
Allopurinol	125	11.7	11.7
Fluticasone Furoate	10	11.2	11.2
Moxifloxacin	11	10.6	10.6
Umeclidinium Bromide And Vilanterol Trifenatate	13	10.6	10.6
Busulfan	12	10.4	10.4
Benralizumab	15	10.2	10.2
Diclofenac Potassium	8	10.0	10.0
Doxycycline Hyclate	48	9.9	9.9
Doxycycline	48	9.8	9.8
Mometasone Furoate And Formoterol Fumarate Dihydrate	11	9.6	9.6
Anakinra	10	8.2	8.2
Varenicline Tartrate	46	8.0	8.0
Linagliptin	10	7.4	7.4
Pancrelipase	20	7.1	7.1
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	21	6.9	6.9
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	6.5	6.5
Fluticasone Propionate And Salmeterol	18	5.9	5.9
Dronedarone	4	5.3	5.3
Buprenorphine Hydrochloride, Naloxone Hydrochloride	9	5.1	5.1
Sacubitril And Valsartan	30	3.5	3.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.